Only losing 2lb a week on Mounjaro — what the evidence says

SURMOUNT-1 showed wide individual variation in weight loss, a 2lb weekly average across an early treatment period is consistent with trial findings, not a sign of failure.
Weight loss on tirzepatide rarely follows a straight line: slower weeks, plateaus, and faster stretches all appear in real-world use and in trial data.
The dose you're currently on matters, the 2.5mg starter pen is designed to settle your system, not to drive maximum weight loss; results typically build through the titration schedule.
Five percent body-weight loss over six months is the NICE benchmark for assessing whether treatment continues, a steady 2lb a week almost always clears that bar comfortably.

Losing around 2lb a week on Mounjaro is, for many people, a perfectly normal and clinically meaningful rate of progress. SURMOUNT-1, the pivotal trial published in the New England Journal of Medicine, reported average body-weight reductions of around 20–21% over 72 weeks at the highest dose, but that average hides a wide spread. Some participants lost faster; others lost more slowly; the trajectory rarely runs in a straight line. If you're on Mounjaro and the number on the scales is moving by roughly 2lb each week, that places you well within the range seen across thousands of trial participants, and it is far more than the clinically significant 5% threshold that NICE uses to assess whether treatment is working. Mounjaro is a prescription-only medicine, and any decisions about your dose or treatment plan sit with your prescriber rather than a weekly weigh-in figure.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

Why your weekly loss figure tells only part of the story

What the SURMOUNT trial data actually shows about weekly loss

It is easy to look at a headline figure (average 20% weight reduction in 72 weeks) and reverse-engineer an expected weekly number, then worry when your own scales don't match. The problem is that the headline average smooths over everything. In SURMOUNT-1, the 2,539 participants included people who lost very little early on and accelerated later, people who plateaued mid-trial, and people who responded strongly from the outset. No single weekly rate defines "how Mounjaro works."

Two pounds a week, held consistently, would produce roughly 26lb across three months. Over a year that is a substantial, clinically significant change. NICE's appraisal of tirzepatide (TA1026) sets the continuation threshold at 5% body-weight loss after six months, a bar that steady 2lb weeks would clear for most adults. The evidence, in other words, does not suggest that slower is broken.

It is also worth knowing that the trial ran for 72 weeks at the full maintenance dose. Many participants were still losing weight at week 36 and beyond. The curve is long, not steep.

How your current dose shapes what you're losing right now

Mounjaro's UK titration schedule moves from 2.5mg upward in roughly four-week steps, through 5mg, 7.5mg, 10mg, 12.5mg and on to 15mg for those who tolerate and need it. The first pen's job is adjustment (your body learning to work alongside tirzepatide's dual GIP and GLP-1 receptor activity) not maximum appetite suppression.

If you're only a few weeks into treatment, or still at one of the lower doses, a 2lb weekly loss is a reasonable result at that stage. The SURMOUNT-1 data shows the loss curve steepening as doses increase. A prescriber who reviews your progress before each dose step is looking at the whole picture: how you're tolerating the current pen, any side effects, your overall trajectory. A number that feels modest at 5mg may look very different once titration is complete.

You can read more about how Mounjaro works across the full treatment journey on our page on losing weight on Mounjaro, which covers what to expect at each stage.

The other factors that sit behind your weekly number

Body weight is not controlled by medicine alone. Sleep, stress, fluid retention, menstrual cycle, alcohol intake, changes in activity, and how much muscle mass you're maintaining alongside fat loss all shift what the scales show on any given morning. A week where the number barely moves might be a week where fat loss is happening but water retention is masking it.

Protein adequacy matters too. GLP-1 medicines reduce appetite significantly, and some people find they're eating too little protein to preserve muscle. A registered dietitian (or a frank conversation with your prescriber) can identify whether your diet pattern is supporting the medicine as well as it could.

Hair thinning is another question that comes up in this context: rapid weight loss of any cause can trigger temporary shedding, and if that's a concern alongside your rate of loss, our page on hair loss and Mounjaro covers what the evidence says. Separately, if you find yourself only losing 1lb a week on Mounjaro and wondering whether that is cause for concern, our dedicated page looks at why that pattern is more common than many people realise. If you've ever wondered how Mounjaro's cost compares across providers, our Mounjaro pricing page sets out the honest picture.

When to have a conversation with your prescriber

There are situations where a 2lb weekly loss, or any plateau, is worth discussing rather than simply accepting. If you've been on the highest tolerated dose for several months and the trend has completely stopped, that warrants a clinical review. If side effects are limiting how much you can eat in a way that feels unsustainable, that is also a conversation rather than something to push through.

What it is not is a reason to compare your numbers to someone else's. Social media is full of accounts of dramatic early loss, often at doses or starting weights that make direct comparison meaningless. The people whose results you are not seeing are the ones whose trajectories look like yours.

Our prescribers review progress at every repeat, not just at the start. If you have questions about your rate of loss, your dose, or anything your treatment is or isn't doing, that is precisely what those reviews are for. You can learn more about tirzepatide as a medicine, or read about the Mounjaro treatment overview to understand the full clinical context. Some people also find it useful to look at our FAQs before their next review. When you're ready to talk it through, speak to our prescribers, a real clinician reads your answers, the same day.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions